Related Experiment Video
Updated: Jun 26, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
Published on: November 1, 2015
Lessons Learnt from the Belimumab Trials in Systemic Lupus Erythematosus
Leonardo Palazzo1, Alexander Tsoi1, Dionysis Nikolopoulos1
1Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Center for Molecular Medicine (CMM), SE-171 76 Stockholm, Sweden.
Belimumab, a biologic therapy for systemic lupus erythematosus (SLE), effectively reduces disease activity and improves quality of life. Post-marketing studies confirm its durable efficacy and safety across various patient subgroups and organ manifestations.
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Background:
- Belimumab, a monoclonal antibody targeting B-cell activating factor (BAFF), is approved for systemic lupus erythematosus (SLE) management.
- Initial Phase III trials established belimumab's efficacy and safety as an add-on therapy.
- Extensive post hoc analyses and real-world data provide further insights into its clinical utility.
Purpose of the Study:
- To review key findings from post hoc analyses of randomized controlled trials (RCTs) and observational studies of belimumab in SLE.
- To consolidate evidence on belimumab's impact on disease activity, organ-specific manifestations, and patient-reported outcomes.
- To inform future clinical trial design and therapeutic strategies for SLE.
Main Methods:
- Analysis of post hoc data from Phase III RCTs of belimumab in SLE.
- Review of real-world evidence and long-term extension studies.
- Examination of studies focusing on organ-specific manifestations and person-centered outcomes.
Main Results:
- Belimumab consistently improves disease activity, health-related quality of life (HRQoL), and reduces flares, particularly in serologically active SLE.
- Significant benefits observed in musculoskeletal, mucocutaneous, and renal manifestations, including improved renal outcomes in lupus nephritis (LN).
- Long-term data confirm durable efficacy and safety, with sustained reductions in disease activity, glucocorticoid use, and healthcare utilization.
Conclusions:
- Post-marketing evidence enhances understanding of belimumab's role in diverse SLE patient populations and organ involvements.
- Belimumab offers a valuable therapeutic option for managing SLE, improving patient outcomes and quality of life.
- This comprehensive evidence base provides a framework for future SLE research and treatment development.
Related Concept Videos
Assessing Body Temperature - Rectal
Follow these steps for rectal temperature assessment:
Step 1: Perform hand hygiene and don clean gloves to prevent cross-infection.
Step 2: Position the patient in a side-lying position to better visualize the rectal...
Muscles of the Pelvic Floor and Perineum
Perineal Layer
The perineum is a diamond-shaped area below the pelvic diaphragm, divided into an anterior urogenital triangle that contains the external genitals and a posterior anal triangle housing the anus. The urogenital...
Assessment of the Abdomen III: Palpation

